An outside panel of scientific advisers to the Food and Drug Administration narrowly recommended the agency authorize the experimental Covid-19 oral antiviral from Merck & Co. and partner Ridgeback Biotherapeutics LP.
The panel, known as the Antimicrobial Drugs Advisory Committee, voted 13 to 10 in support of the FDA granting use. The recommendation is limited to high-risk people.